U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT06838286) titled 'Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes' on June 30, 2024.
Brief Summary: A multicenter, prospective, non-interventional observation study to evaluate the safety and effectiveness of OAD triple therapy in Korean Type 2 diabetic mellitus patients.
Study Start Date: March 16, 2024
Study Type: OBSERVATIONAL
Condition:
Diabetes Mellitus, Type 2
Intervention:
DRUG: SGLT2 inhibitor
SGLT2 inhibitor class of drugs
DRUG: Thiazolidinedione
Thiazolidinedione class of drugs
DRUG: DPP-4 inhibitor
DPP4 inhibitor class of drugs
Recruitment Status: RECRUITING
Sponsor: Chong Kun Dang Pharmaceuti...